# A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care

> **NCT07712484** · PHASE2 · NOT_YET_RECRUITING · sponsor: **F2G Ltd** · enrollment: 50 (estimated)

## Conditions studied

- Coccidioidomycosis
- Disseminated Fungal Infection
- Coccidioides Infection
- Coccidioides Immitis Infection
- Coccidioides Posadasii Infection
- Coccidioidomycosis Infection
- San Joaquin Valley Fever
- Valley Fever

## Interventions

- **DRUG:** Olorofim
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07712484
- **Lead sponsor:** F2G Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2028-06
- **Final completion:** 2028-07
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712484, "A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07712484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*